Please ensure Javascript is enabled for purposes of website accessibility

Why Regeneron Pharmaceuticals Shares Rose 10% in March?

By Anne Burdakin - Apr 8, 2020 at 2:25PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company that created a successful Ebola treatment takes aim at COVID-19.

What happened

While the bottom was falling out for a lot of stocks in March, shares of Regeneron Pharmaceuticals (REGN 0.77%) actually went up 10%, according to data provided by S&P Global Market Intelligence.

In mid-March, Regeneron announced progress in developing a multi-antibody cocktail to prevent infection from the coronavirus or to treat those already infected. 

Separate from the antibody cocktail, Regeneron and collaborator Sanofi (SNY 2.19%) announced clinical trials to evaluate the drug Kevzara, currently used to treat patients with rheumatoid arthritis, as a treatment for COVID-19. The drug may help control the overactive inflammatory response in the lungs of severely ill COVID-19 patients. That means Kevzara may be able to prevent a critically ill patient's immune system from overreacting and attacking the body's own organs. 

Finally, at the very end of February, Novartis (NVS 0.12%), a key competitor in the macular degeneration market, had a safety setback, which positions Regeneron's drug Eylea to outperform. With estimated 2020 revenue set at $4.58 billion, Eylea is the dominant player in macular degeneration treatment, and Regeneron wants it to stay that way.

Scientist peering into a microscope

Image source: Getty Images.

So what

Regeneron has a long list of successful drugs, but the potential COVID-19 vaccine and treatments have been driving the stock price up while most others are down sharply. Whichever drug company successfully produces the desperately needed treatment first will reap huge rewards, since the demand is worldwide.

In the race among pharmaceutical companies to come up with a successful vaccine and various treatments, I think Regeneron has the best shot at finding what is needed in the shortest period of time.

Why? First of all, the company has experience rapidly developing a successful treatment, as it did for the Ebola virus. And second, Regeneron's proprietary VelociMab technology can prepare cell lines ready for manufacturing as soon as lead antibodies are selected, so clinical-scale production can begin immediately. 

Now what

Regeneron sports a price-to-earnings ratio of 27, versus a sector average of 28, and the S&P average of 27.

Regeneron's P/E seems pretty reasonable given the possible benefit of developing coronavirus treatments. And the underlying business, built over 30 years, has drugs in every phase of maturation. In addition, the drug pipeline of new treatments in clinical trials has over 20 products. Regeneron is a solid business even without coronavirus drugs.

Given the company's capabilities of moving quickly and safely toward both a coronavirus vaccine and treatments (not just one or the other) and Regeneron's solid business, the stock is attractive. Investors would do well to initiate or add to a position in this stock. 

Anne Burdakin has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Regeneron Pharmaceuticals, Inc. Stock Quote
Regeneron Pharmaceuticals, Inc.
$628.71 (0.77%) $4.81
Sanofi Stock Quote
$44.37 (2.19%) $0.95
Novartis AG Stock Quote
Novartis AG
$85.68 (0.12%) $0.10

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/12/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.